18FDG PET Applications in Gastrointestinal Oncology
18FDG PET/CT is a molecular imaging technique that evaluates the metabolic activity of gastrointestinal (GI) tumors, assisting in diagnosis, staging, and monitoring of treatment response. While it is a valuable imaging technique for detecting malignancy, evaluating recurrence, and assessing treatment efficacy, it has moderate specificity due to physiological FDG uptake in inflammatory lesions and limited spatial resolution compared to computed tomography (CT) or magnetic resonance imaging (MRI).
Esophageal and Gastric Cancer:
18FDG PET/CT is more sensitive than CT for detecting metastases and can help identify patients who responded early to chemotherapy.
Main indications for 18FDG PET/CT examination
Initial staging in patients who are candidates for radical surgical treatment.
Restaging following therapy.
In cases of suspected recurrence, when other imaging findings are inconclusive.
Colorectal Cancer:
FDG PET/CT is particularly effective for diagnosing disease recurrence, especially when tumor markers are elevated without definitive or with equivocal findings on conventional imaging.
Main indications for 18FDG PET/CT examination
Staging prior to therapeutic metastasectomy.
Detection of recurrence in patients with elevated tumor markers and/or clinical suspicion, with negative or equivocal findings on other imaging modalities.
Assessment of response to targeted interventional techniques (radiofrequency ablation, chemoembolization/radioembolization) or chemoradiotherapy.
Pancreatic Cancer:
The role of 18F-FDG PET/CT in pancreatic cancer focuses on improving initial diagnosis and staging, particularly for detecting occult distant metastases in locally advanced/borderline resectable cases and for evaluating treatment response following neoadjuvant therapy (NAT).
Main indications for 18FDG PET/CT examination
Evaluation of patients with known pancreatic cancer who are candidates for radical surgical treatment, with other imaging findings negative or equivocal for metastatic disease, and restaging following preoperative therapy.
In cases of suspected pancreatic cancer recurrence, with suspicious findings on conventional imaging.
Hepatobiliary Cancer
FDG PET/CT examination is a valuable tool in the diagnosis and management of high-grade hepatocellular carcinoma (HCC) and cholangiocarcinoma, particularly for staging, detection of distant metastases, evaluation of therapeutic response, and prognosis prediction.
Main indications for 18FDG PET/CT examination
Evaluation of patients with known cholangiocarcinoma or high-grade hepatocellular carcinoma who are candidates for radical surgical treatment or transplantation, with other imaging findings negative or equivocal for metastatic disease.
In cases of suspected recurrence of cholangiocarcinoma or high-grade hepatocellular carcinoma, with equivocal results on conventional imaging.
Assessment of response to targeted interventional techniques (radiofrequency ablation, chemoembolization/radioembolization) or chemoradiotherapy.
Gastrointestinal Stromal Tumors (GIST)
FDG PET/CT examination is a powerful diagnostic tool for gastrointestinal stromal tumors (GIST) that assists in evaluating biological risk and treatment response. Main indications for 18FDG PET/CT examination
Biological Risk Assessment: High FDG uptake in a GIST suggests a higher metabolic rate and increased risk of malignant behavior, which can help predict prognosis and inform management strategies.
Staging and Recurrence Detection: While CT is excellent for detecting metastases, FDG PET/CT can identify small or subtle recurrences, especially in cases of suspected clinical disease progression or when CT findings are equivocal or unclear.
Monitoring Treatment Response: FDG PET/CT can demonstrate decreased tumor metabolic activity (indicated by lower FDG uptake) much earlier than visible anatomical changes on CT, providing a faster assessment of how well a targeted therapy is working.